Bio Medica Laboratories IPO

About Bio Medica Laboratories IPO

The 100% book building issue of Bio Medica Laboratories comprises a fresh issue of aggregating up to 32,05,200 equity shares and an offer for sale aggregating up to 3,76,800 equity shares. The total number of shares in this IPO is 37,71,600. The price band is [TBA] per share and the lot size is [TBA]. The IPO opens on [TBA] and closes on [TBA].

The listing date is on [TBA] and the allotment date is on [TBA]. The credit of shares to the Demat account will take place on [TBA], while the initiation of refund will take place on [TBA]. Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations. It manufactures a variety of products, comprising ethical drugs, generic drugs and over-the-counter drugs (OTC) in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences.

Objectives of Bio Medica Laboratories IPO

The company proposes to utilise the IPO proceeds for:

• Repayment of loan
  
• Enhancement of its existing production capabilities by setting up of new manufacturing facility at the
  
• existing premises
  
• General corporate purposes
  

Market maker reservation portion is 5.03% of the issue size.

Industry Outlook

The Indian pharmaceutical industry is the world’s 3rd largest by volume of production and plays a significant role globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and one of the largest suppliers of low-cost vaccines in the world.

Indian manufacturers account for 60 percent of the vaccine supplies to UNICEF, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine.

The Indian CRDMO industry is one of the fastest-growing globally, having grown at a CAGR of 12.6% between 2018 and 2023. India is an emerging hub for pharma innovators and is gaining significant prominence due to multiple growth tailwinds in the APAC region.

The Indian CRDMO is poised to grow at 14% CAGR between 2023 and 2028 to reach an estimated value of USD 14.1 billion in 2028, outpacing the global industry rate of 9.0% (2023 to 2028) and other markets such as the PRC due to the implementation of the US BIOSECURE Act, which makes India a front runner in the CRDMO outsourcing business.

With multiple structural tailwinds in place and supported by the strong credentials of Indian CRO and CDMO players, India will likely garner a higher share of the global pharma outsourcing industry.

Company Information

Bio Medical Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations. It manufactures a variety of products, including ethical drugs, generic drugs and over-the-counter drugs (OTC) in the form of injectables namely Liquid Injections and Dry Powder Injections.

These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences.

Strengths of Bio Medica Laboratories

• Experienced promoters, management and employees
  
• Quality assurance
  
• Multi-product capability and diversified product portfolio
  
• Established client relationship
  
• Low attrition rate of employees
  

Risks of Bio Medica Laboratories IPO

• Loss of any key client could adversely affect business, financial condition and results of operations
  
• Quality control problems may damage reputation for high quality products and expose the company to litigation or other liabilities
  
• Inability to adopt new technologies could adversely affect business
  
• Sustained negative cash flow could have an impact on the company’s growth and business
  
• The company does not own the premises through which it conducts its business operations
  

IPO Registrar and Book Running Lead Manager

• Registrar: Skyline Financial Services Pvt
• Book Running Lead Manager: Narnolia Financial Services

Business Model

Bio Medica Laboratories operates on a B2B business model through contract manufacturing and does not deal directly with the end users. The company manufactures formulations for various companies according to their specific requirements and specifications for the type of formulation needed.

Additionally, it enters into agreements with them, allowing their name and address to be displayed on the packaging as "Technical Collaborator" or “marketed by” alongside the company’s name as the manufacturer.

Company Growth Trajectory

The revenue from operations of Bio Medica Laboratories grew from ₹16.2282 crores in FY 23 to ₹38.1952 crores in FY 25. Its EBITDA margin increased from 10.47% in FY 23 to 39.83% in FY 25. Diversified product portfolio coupled with quality assurance has helped the company grow over the years.

Market Position

Bio Medica Laboratories holds a Good Manufacturing Practices (GMP) certificate issued by Food & Drugs Administration, Madhya Pradesh, for complying with established GMP standards and guidelines. It supplies its products in different Indian states including Arunachal Pradesh, Chhattisgarh, Gujarat, Haryana, Karnataka, Madhya Pradesh, Tamil Nadu, West Bengal, Telangana, Uttar Pradesh and Rajasthan, among others.

How to Check Allotment Status of Bio Medica Laboratories?

1. Visit the Registrar’s Website

• Visit the official website of Skyline Financial Services Pvt
• Click on ‘Public Issue’ from ‘Investors’ dropdown
• Choose ‘Company Name’
• Enter DPID/Client ID or Application Number or PAN Number
• Click on ‘Search’ to know the status

2. Verify on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. You can use it to check the status of Bio Medica Laboratories IPO. Go to the NSE website and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.

On the NSE IPO Bid Verification page, enter:

• Company name from dropdown
  
• Application number
  
• PAN
  

Then click 'Submit' to know the allotment status.

How to Apply for Bio Medica Laboratories IPO?

• Log in to your Kotak Securities Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
  
• Specify IPO details - Enter the number of lots and the price you wish to apply for.
  
• Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
  
• Mandate Notification - Your UPI app will receive a mandate notification to block funds.
  
• Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.